Considerations in Scale-Up of Viral Vaccine Production

摘要

On 28 June 2011, the Food and Agriculture Organization of the United Nations declared the Rinderpest cattle plague virus to be the second troublesome virus (after smallpox) that humans have eradicated from the Earth (l). Such achievements herald exciting times both for classical vaccinology and for many new and developing technologies. Here we consider scaling up of vaccines and related hybrid, targeted, and conjugated viral therapeutics that are made through animal cell culture. The vaccine industryis now moving from production in platforms based on whole animals and primary tissues (e.g., embryonated chicken eggs) to cultured-cell-based production (2). This transition began over 50 years ago with polio vaccine development. It is still in progresstoday, as evidenced by Baxter International's recent European introduction of influenza vaccine produced by Vero cell culture. And the soon-to-open Novartis plant in Holly Springs, NC, one of the first producing flu vaccine by cell culture in the UnitedStates.